{"slug":"cancer-immunotherapy","topic":"cancer-immunotherapy","title":"Cancer Immunotherapy: State of the Field (October 2026)","summary":"Covers checkpoint inhibitors, T-cell engagers, CAR and TIL cell therapies, and antibody-drug conjugates, with emphasis on predictive biomarkers, immune-related toxicity and the newest published evidence through 2026. The central takeaway is that response prediction and toxicity management remain the binding constraints, and that single markers such as PD-L1 cover only a minority of approvals.","version":1,"published_at":"2026-10-30","updated_at":"2026-10-30","stats":{"words":4339,"citations":64,"claims":28,"timeline":16,"benchmarks":11,"open_problems":9,"key_papers":15,"glossary":14},"verification":{"status":"verified","method":"automated figure and citation-relevance triage against cited abstracts, plus targeted AI review with web checks of flagged statements; automated citation resolution","claims_checked":22,"issues_fixed":5,"verified_at":"2026-10-30"},"ai_assisted":true,"price":{"usd":"0.20","protocol":"x402","network":"eip155:84532","asset":"USDC"},"url":"https://space-kitty.com/dossiers/cancer-immunotherapy","preview_url":"https://space-kitty.com/api/v1/dossiers/cancer-immunotherapy/preview","purchase_url":"https://space-kitty.com/api/v1/dossiers/cancer-immunotherapy","toc":[{"level":2,"text":"Executive summary","anchor":"executive-summary"},{"level":2,"text":"Background and core concepts","anchor":"background-and-core-concepts"},{"level":2,"text":"Timeline of key milestones","anchor":"timeline-of-key-milestones"},{"level":2,"text":"State of the art","anchor":"state-of-the-art"},{"level":3,"text":"Checkpoint inhibitors and predictive biomarkers","anchor":"checkpoint-inhibitors-and-predictive-biomarkers"},{"level":3,"text":"Immune-related toxicity and its management","anchor":"immune-related-toxicity-and-its-management"},{"level":3,"text":"T-cell engagers and cell therapy","anchor":"t-cell-engagers-and-cell-therapy"},{"level":3,"text":"Antibody-drug conjugates","anchor":"antibody-drug-conjugates"},{"level":3,"text":"Combinations and myeloid targets","anchor":"combinations-and-myeloid-targets"},{"level":3,"text":"Quantitative benchmarks","anchor":"quantitative-benchmarks"},{"level":2,"text":"Open problems and active debates","anchor":"open-problems-and-active-debates"},{"level":2,"text":"Major programs and players","anchor":"major-programs-and-players"},{"level":2,"text":"Outlook: what to watch (next 12-18 months)","anchor":"outlook-what-to-watch-next-12-18-months"},{"level":2,"text":"Key papers","anchor":"key-papers"},{"level":2,"text":"Glossary","anchor":"glossary"}],"sample_claims":["In a 2026 systematic review of 32 studies, late-onset immune checkpoint inhibitor myocarditis (presentation at least 90 days after the first dose) had a median onset of 9.0 months (IQR 6.2-12.8) among the 30 cases with timing data.","In a 2026 single-centre retrospective cohort of 768 lung cancer patients treated with checkpoint inhibitors, rheumatologist-confirmed rheumatic immune-related adverse events occurred in 8.6% (66 patients)."],"includes":["markdown","claims","timeline","benchmarks","open_problems","key_papers","glossary","bibliography"],"citation_count":64,"how_to_buy":"GET https://space-kitty.com/api/v1/dossiers/cancer-immunotherapy with an x402 client ($0.20, USDC on Base Sepolia (testnet))."}